Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.
Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy.
Phase-III clinical trial is initiated to evaluate the efficacy and safety of Molnupiravir Capsules in mild COVID-19 patients. NATCO s clinical trial is planned in 32 hospitals across India. A few established hospitals locally include Yashoda Hospitals, Gleneagles Global Hospitals, KIMS Hospital in Secunderabad and Vizag, and Excel Hospital, where the trial is being conducted.
Powered by Capital Market - Live News
NATCO starts Phase-III Clinical Trial of Molnupiravir capsules for Covid-19 treatment equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
SINGAPORE: Mitsui & Co is exploring a deal to take Malaysian hospital group IHH Healthcare Bhd private, according to people with knowledge of the matter.
Some private equity firms have approached the Japanese trading house to team up on the potential transaction to buy out IHH’s other shareholders, said one of the people, who asked not to be named as the information is private.
Mitsui has reached out to Khazanah Nasional Bhd, IHH’s second-largest shareholder, to pick up its stake, another person said.
IHH, which is listed on the stock exchanges of Malaysia and Singapore, has a market value of RM49bil (US$12bil).
Global healthcare provider IHH Healthcare has entered into a partnership with Bharat Biotech to provide Covaxin at its Gleneagles Global Hospitals in three locations in India.“Three of the IHH Healthc
Ocugen to seek emergency-use nod for Covaxin in US market
May 04, 2021
Covaxin demonstrates potential effectiveness against different variants, says study
Ocugen, the US partner of Bharat Biotech for its Covid-19 vaccine Covaxin, is set to seek the US Food and Drug Administration’s nod for emergency-use authorisation of the vaccine in the US market.
The Ocugen team has submitted a comprehensive drug master file with the FDA, and is currently diligently preparing the EUA application, according to Shankar Musunuri, Chairman of the Board, CEO and and co-founder of Ocugen.
In February, Hyderabad-based Bharat Biotech and Ocugen entered into a pact, according to which the latter will co-develop, supply, and commercialise Covaxin.